MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-01-2026
Tilray Total Current Liabilities 2011-2026 | TLRY
Annual Total Current Liabilities Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 433 M | 280 M | 401 M | 181 M | 92.4 M | 25.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 433 M | 25.9 M | 236 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
10.4 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
36.7 M | $ 5.66 | 1.07 % | $ 84.1 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
7.71 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
48.2 M | $ 2.67 | -0.37 % | $ 1.02 B |  Canada |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
96.3 M | $ 39.05 | 3.75 % | $ 1.44 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.01 | 1.5 % | $ 109 M | Canada |
 |
Organogenesis Holdings
ORGO
|
100 M | $ 2.37 | 1.28 % | $ 300 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 22.96 | -0.15 % | $ 1.06 B | USA |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 7.34 | 2.8 % | $ 642 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 1.12 | 2.84 % | $ 1.39 M | USA |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
75.3 M | $ 6.67 | -0.89 % | $ 430 M | USA |
 |
Emergent BioSolutions
EBS
|
132 M | $ 8.3 | -0.24 % | $ 444 M | USA |
 |
Veru
VERU
|
7.79 M | $ 3.07 | 2.43 % | $ 45 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
3.19 M | $ 0.71 | 3.49 % | $ 2.86 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | $ 23.49 | 0.02 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
53.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
4.18 B | $ 5.08 | 0.4 % | $ 1.88 B | Canada |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.72 | 1.05 % | $ 265 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
163 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 4.33 | 2.36 % | $ 216 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
7.09 B | $ 16.46 | -0.12 % | $ 19.3 B | USA |
 |
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
9.58 M | $ 0.65 | 3.92 % | $ 23.4 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
7.4 M | $ 0.75 | 1.01 % | $ 3.22 M |  China |
 |
TherapeuticsMD
TXMD
|
4.78 M | $ 2.26 | 2.73 % | $ 26.1 M | USA |